Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab and Erlotinib in advanced NSCLC
NCT02507375Phase 1Completed
- Sponsor
- Roche
- Start
- Sep 2006
- Primary completion
- Dec 2008
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of pertuzumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Dose Limiting Toxicities at 42 weeks. Started Sep 2006; status: completed.
02
Drugs
pertuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02507375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507375.